Trial · NCT03779113
Results by group395
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 395
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Dose Escalation Stage: Number of Patients With Dose-Limiting Toxicities (DLTs) | Dose Escalation Stage: HMPL-523 100 mg QD | 1 | Participants | ||
| Dose Escalation Stage: Number of Patients With Dose-Limiting Toxicities (DLTs) | Dose Escalation Stage: HMPL-523 200 mg QD | 0 | Participants | ||
| Dose Escalation Stage: Number of Patients With Dose-Limiting Toxicities (DLTs) | Dose Escalation Stage: HMPL-523 400 mg QD | 0 | Participants | ||
| Dose Escalation Stage: Number of Patients With Dose-Limiting Toxicities (DLTs) | Dose Escalation Stage: HMPL-523 600 mg QD | 0 | Participants | ||
| Dose Escalation Stage: Number of Patients With Dose-Limiting Toxicities (DLTs) | Dose Escalation Stage: HMPL-523 700 mg QD | 0 | Participants | ||
| Dose Escalation Stage: Number of Patients With Dose-Limiting Toxicities (DLTs) | Dose Escalation Stage: HMPL-523 800 mg QD | 2 | Participants | ||
Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment Discontinuation | Dose Escalation Stage: HMPL-523 100 mg QD | Any TEAE | 4 | Participants | |
Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment Discontinuation | Dose Escalation Stage: HMPL-523 200 mg QD | Any TEAE | 3 | Participants | |
Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment Discontinuation | Dose Escalation Stage: HMPL-523 400 mg QD | Any TEAE | 3 | Participants | |
Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment Discontinuation | Dose Escalation Stage: HMPL-523 600 mg QD | Any TEAE | 3 | Participants | |
Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment Discontinuation | Dose Escalation Stage: HMPL-523 700 mg QD | Any TEAE | 4 | Participants | |
Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment Discontinuation | Dose Escalation Stage: HMPL-523 800 mg QD | Any TEAE | 4 | Participants | |
Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment Discontinuation | Dose Escalation Stage: HMPL-523 100 mg QD | Any Treatment related TEAE | 3 | Participants | |
Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment Discontinuation | Dose Escalation Stage: HMPL-523 200 mg QD | Any Treatment related TEAE | 3 | Participants | |
Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment Discontinuation | Dose Escalation Stage: HMPL-523 400 mg QD | Any Treatment related TEAE | 3 | Participants | |
Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment Discontinuation | Dose Escalation Stage: HMPL-523 600 mg QD | Any Treatment related TEAE | 3 | Participants | |
Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment Discontinuation | Dose Escalation Stage: HMPL-523 700 mg QD | Any Treatment related TEAE | 3 | Participants | |
Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment Discontinuation | Dose Escalation Stage: HMPL-523 800 mg QD | Any Treatment related TEAE | 3 | Participants | |
Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment Discontinuation | Dose Escalation Stage: HMPL-523 100 mg QD | Any TEAE leading to treatment interruption | 1 | Participants | |
Dose Escalation Stage: Number of Patients With Treatment-Emergent Adverse Events, Treatment Related Treatment-Emergent Adverse Events, Treatment-Emergent Adverse Events Leading to Treatment Interruption, Treatment Reduction and Treatment Discontinuation | Dose Escalation Stage: HMPL-523 200 mg QD | Any TEAE leading to treatment interruption | 2 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03779113/results